A myoclonic reaction with low-dose hydromorphone

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 2068-2070

  Patel, Seema ^a,b   Roshan, Veda R ^a,c   Lee, Kelly C ^a   Cheung, Rebecca J ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Hydromorphone; Myoclonus; Toxicity

Indexed keywords

ATENOLOL; DISOPYRAMIDE; ENALAPRIL; FLUTICASONE PROPIONATE PLUS SALMETEROL; GABAPENTIN; HYDROMORPHONE; ONDANSETRON; OXYCODONE; SIMVASTATIN; VENLAFAXINE; WARFARIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DEPRESSION; DRUG EFFECT; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MYOCLONUS; NARANJO PROBABILITY SCALE; NEUROTOXICITY; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SYMPTOM; THORAX PAIN; VOMITING;

DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; MYOCLONUS; PAIN;

EID: 33750975108     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H243     Document Type: Article

References (11)

1. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide, a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-20.
2. Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-50.
3. Zheng M, McErlane KM, Ong MC. Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 2002;32:427-39.
4. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993;24:334-54.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 1997;14:51-8.
8. Wright AW, Nocente ML, Smith MT. Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998;63:401-11.
9. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure (letter). J Pain Symptom Manage 1995;10:184-6.
10. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-8.
11. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.